Published in Sci Rep on July 15, 2015
The MAGE protein family and cancer. Curr Opin Cell Biol (2015) 1.00
Prognostic Value of KIF2A and HER2-Neu Overexpression in Patients With Epithelial Ovarian Cancer. Medicine (Baltimore) (2016) 0.79
MAGE-A Antigens and Cancer Immunotherapy. Front Med (Lausanne) (2017) 0.78
EphA8 is a prognostic marker for epithelial ovarian cancer. Oncotarget (2016) 0.77
A Comprehensive Guide to the MAGE Family of Ubiquitin Ligases. J Mol Biol (2017) 0.75
LTBP2 is a prognostic marker in head and neck squamous cell carcinoma. Oncotarget (2016) 0.75
The prognostic implications of growth-related gene product β in laryngeal squamous cell carcinoma. Oncol Lett (2017) 0.75
Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer (2005) 9.46
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A (1997) 6.67
X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res (2004) 6.22
An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res (2001) 3.08
Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res (2005) 2.73
Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res (2010) 2.19
The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease. J Neurosci Res (2002) 2.00
Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol (2013) 1.91
Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol (2013) 1.67
Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin Cancer Res (2003) 1.64
The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. Cancer Res (2008) 1.53
Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics. Clin Cancer Res (2012) 1.44
MAGE-A gene expression pattern in primary breast cancer. Cancer Res (2001) 1.34
Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue. Clin Cancer Res (2005) 1.24
Prognostic value of LAMP3 and TP53 overexpression in benign and malignant gastrointestinal tissues. Oncotarget (2014) 1.19
High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer. Int J Cancer (2009) 1.16
An overview of biomarkers for the ovarian cancer diagnosis. Eur J Obstet Gynecol Reprod Biol (2011) 1.16
Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration. Lung (2009) 1.12
The clinical significance of MAGEA3 expression in pancreatic cancer. Int J Cancer (2006) 1.11
Targeted therapies for non-small cell lung cancer: an evolving landscape. Mol Cancer Ther (2010) 1.07
ROR1 expression correlated with poor clinical outcome in human ovarian cancer. Sci Rep (2014) 1.04
Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy. Haematologica (2011) 1.00
Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer. PLoS One (2014) 0.96
A cleaved form of MAGE-A4 binds to Miz-1 and induces apoptosis in human cells. J Biol Chem (2004) 0.95
High expression of MAGE-A9 correlates with unfavorable survival in hepatocellular carcinoma. Sci Rep (2014) 0.95
MAGE-A9 mRNA and protein expression in bladder cancer. Int J Cancer (2007) 0.92
Expressions of MAGE-A9 and MAGE-A11 in breast cancer and their expression mechanism. Arch Med Res (2013) 0.91
Tumor-specific antigens in cutaneous T-cell lymphoma: expression and sero-reactivity. Int J Cancer (2003) 0.89
Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor. J Thorac Oncol (2008) 0.89
Prognostic value of melanoma-associated antigen A9 in renal cell carcinoma. Scand J Urol (2012) 0.89
Expression and prognostic value of MAGE-A9 in laryngeal squamous cell carcinoma. Int J Clin Exp Pathol (2014) 0.87
MAGE expressions mediated by demethylation of MAGE promoters induce progression of non-small cell lung cancer. Anticancer Res (2011) 0.87
Overexpression of MAGE-A9 predicts unfavorable outcome in breast cancer. Exp Mol Pathol (2014) 0.87
Expression of MAGE gene family in lung cancers. Kurume Med J (1996) 0.84
Mass spectrometric screening of ovarian cancer with serum glycans. Dis Markers (2014) 0.83
A systematic approach to identify novel cancer drug targets using machine learning, inhibitor design and high-throughput screening. Genome Med (2014) 0.82
Evaluation of MAGE A1 in oral squamous cell carcinoma. Oncol Rep (2012) 0.78
Surgical intervention in relapsed ovarian cancer is beneficial: contra. Ann Oncol (2013) 0.77
High expression levels of MAGE-A9 are correlated with unfavorable survival in lung adenocarcinoma. Oncotarget (2016) 0.80
EphA8 is a prognostic marker for epithelial ovarian cancer. Oncotarget (2016) 0.77